Bharaj IS, Brar AS, Kahlon J, Singh A, Hotwani P, Kumar V, Sohal A, Batta A. Metabolic-dysfunction associated steatotic liver disease and atrial fibrillation: A review of pathogenesis. World J Cardiol 2025; 17(6): 106147 [DOI: 10.4330/wjc.v17.i6.106147]
Corresponding Author of This Article
Aalam Sohal, MD, Department of Gastroenterology and Hepatology, Creighton University School of Medicine, 3216 NE 45th Pl Suite 212, Phoenix, AZ 85012, United States. aalamsohal@gmail.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Review
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Inderjeet Singh Bharaj, Jasraj Kahlon, Department of Internal Medicine, Abrazo Health Network, Glendale, AZ 85308, United States
Ajit Singh Brar, Department of Internal Medicine, Michigan State University at Hurley Medical Center, Flint, MI 48503, United States
Anmol Singh, Department of Medicine, Tristar Centennial Medical Center, Nashville, TN 37203, United States
Priya Hotwani, Department of Internal Medicine, Parkview Health Internal Medicine Residency, Fort Wayne, IN 46845, United States
Vikash Kumar, Aalam Sohal, Department of Gastroenterology and Hepatology, Creighton University School of Medicine, Phoenix, AZ 85012, United States
Akash Batta, Department of Cardiology, Dayanand Medical College and Hospital, Ludhiana 141001, Punjab, India
Author contributions: Bharaj IS and Sohal A conceptualized and designed the study; Bharaj IS, Brar AS, Kahlon J, Hotwani P, Kumar V and Singh A conducted the literature review, interpreted data, created artwork, and drafted the original manuscript; Bharaj IS, Batta A and Sohal A supervised the study and made critical revisions.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Aalam Sohal, MD, Department of Gastroenterology and Hepatology, Creighton University School of Medicine, 3216 NE 45th Pl Suite 212, Phoenix, AZ 85012, United States. aalamsohal@gmail.com
Received: February 17, 2025 Revised: April 9, 2025 Accepted: May 21, 2025 Published online: June 26, 2025 Processing time: 123 Days and 3.7 Hours
Core Tip
Core Tip: Metabolic dysfunction-associated steatotic liver disease (MASLD) and atrial fibrillation (AF) share common metabolic risk factors, including obesity, diabetes, dyslipidemia, and hypertension. Pathophysiological mechanisms such as systemic inflammation, oxidative stress, insulin resistance, and renin-angiotensin-aldosterone system activation link MASLD to AF. Chronic inflammation and oxidative stress in MASLD lead to atrial remodeling, creating an arrhythmogenic substrate. Effective management of MASLD requires targeted risk-factor modification strategies and a multidisciplinary approach to reduce cardiovascular risk and prevent arrhythmias. Early detection and comprehensive management are crucial to mitigate the dual burden of MASLD and AF.
